Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients

The introduction of protease inhibitors (PI) containing antiretroviral regimens in the treatment of HIV infection in infants, children, and adolescents has dramatically decreased morbidity and mortality. Darunavir, the latest PI to be FDA approved for pediatric patients older than 6 years and curren...

Descripción completa

Detalles Bibliográficos
Autores principales: Dobroszycki, Joanna, Abadi, Jacobo, Wiznia, Andrew A, Rosenberg, Michael G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926773/
https://www.ncbi.nlm.nih.gov/pubmed/24600277
http://dx.doi.org/10.2147/AHMT.S11177
_version_ 1782304018537644032
author Dobroszycki, Joanna
Abadi, Jacobo
Wiznia, Andrew A
Rosenberg, Michael G
author_facet Dobroszycki, Joanna
Abadi, Jacobo
Wiznia, Andrew A
Rosenberg, Michael G
author_sort Dobroszycki, Joanna
collection PubMed
description The introduction of protease inhibitors (PI) containing antiretroviral regimens in the treatment of HIV infection in infants, children, and adolescents has dramatically decreased morbidity and mortality. Darunavir, the latest PI to be FDA approved for pediatric patients older than 6 years and currently the preferred PI for use in adult patients, was added as an alternative PI for use in children based on a combination of data from both adult and pediatric trials. This review of darunavir in the treatment of HIV-infected children and adolescents looks at the major published clinical trials findings, pharmacokinetic and resistance studies, and preliminary data on use in younger children.
format Online
Article
Text
id pubmed-3926773
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-39267732014-03-05 Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients Dobroszycki, Joanna Abadi, Jacobo Wiznia, Andrew A Rosenberg, Michael G Adolesc Health Med Ther Review The introduction of protease inhibitors (PI) containing antiretroviral regimens in the treatment of HIV infection in infants, children, and adolescents has dramatically decreased morbidity and mortality. Darunavir, the latest PI to be FDA approved for pediatric patients older than 6 years and currently the preferred PI for use in adult patients, was added as an alternative PI for use in children based on a combination of data from both adult and pediatric trials. This review of darunavir in the treatment of HIV-infected children and adolescents looks at the major published clinical trials findings, pharmacokinetic and resistance studies, and preliminary data on use in younger children. Dove Medical Press 2011-09-14 /pmc/articles/PMC3926773/ /pubmed/24600277 http://dx.doi.org/10.2147/AHMT.S11177 Text en © 2011 Dobroszycki et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Dobroszycki, Joanna
Abadi, Jacobo
Wiznia, Andrew A
Rosenberg, Michael G
Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients
title Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients
title_full Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients
title_fullStr Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients
title_full_unstemmed Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients
title_short Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients
title_sort profile of darunavir in the treatment of hiv-infected pediatric and adolescent patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926773/
https://www.ncbi.nlm.nih.gov/pubmed/24600277
http://dx.doi.org/10.2147/AHMT.S11177
work_keys_str_mv AT dobroszyckijoanna profileofdarunavirinthetreatmentofhivinfectedpediatricandadolescentpatients
AT abadijacobo profileofdarunavirinthetreatmentofhivinfectedpediatricandadolescentpatients
AT wizniaandrewa profileofdarunavirinthetreatmentofhivinfectedpediatricandadolescentpatients
AT rosenbergmichaelg profileofdarunavirinthetreatmentofhivinfectedpediatricandadolescentpatients

Ejemplares similares